Treatment with growth hormone-releasing hormone (GHRH) 1-44 in children with idiopathic growth hormone deficiency: a randomized double-blind dose-effect study. The GHRH European Multicenter Study (GEMS) Group

What Was Tested

Researchers studied GHRH (Growth Hormone-Releasing Hormone) in this randomized controlled trial publication.

Who Took Part

The abstract describes 70 boys taking part.

The age groups tagged for this paper are young children, children and teenagers, both men and women.

One hundred and eleven pre-pubertal children (70 boys, 41 girls, aged 2.5 to 14.3 years) with growth failure (height 2 SD below the mean for chronological age (CA) and height velocity (HV) below the 10th percentile for bone age) due to idiopathic growth hormone deficiency (peak plasma GH < 20 mUI/1 to two standard provocative tests) were treated with GHRH 1-44 NH2.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The boys were allocated by chance, so the GHRH (Growth Hormone-Releasing Hormone) group and the comparison group should start out alike.

As a double-blind GHRH (Growth Hormone-Releasing Hormone) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with GHRH (Growth Hormone-Releasing Hormone) could be set against what happens without it.

What Was Measured

The subject headings attached to it are Body Height, Growth Hormone, Growth Hormone-Releasing Hormone, Pancreatic Hormones, Patient Compliance and Peptide Fragments.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of GHRH (Growth Hormone-Releasing Hormone) in 70 boys.

The publication is from 1992 (Fundamental & clinical pharmacology), a journal based in England.

More context: the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.